Enhancement of Treatment of Delusions in Schizophrenia Through Neuromodulation (tACS)
Schizophrenia, Psychosis, Delusions
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria:
- Patients between the ages of 19 to 60 years with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis not otherwise specified, or a mood disorder with psychotic features will be recruited for this study.
Exclusion Criteria:
- An inability to read and write in English. Participants must be have used English on a daily basis for at least 5 years, and must be able to understand the consent form and give written consent.
- Participants with an IQ score of 80 or lower.
- A history of severe neurological disorder and those with severe manifestations of hostility, megalomania, formal thought disorder and suspiciousness will also be excluded from the analysis.
- Subjects who are consistently disrupting the treatment group might be asked to leave, this will be at the discretion of the group instructor.
- A history of neurological problems (e.g., stroke, aneurysm, Parkinson's, Multiple Sclerosis, encephalitis, meningitis, etc.)
- History of seizure disorder or family history of seizure disorder.
- History of migraines or other types of frequent severe headaches.
- Metallic implants in head.
- Severe head injury, frequent loss of consciousness and/or loss of consciousness greater than 30 minutes.
- Recently suffered a serious concussion
- Pregnancy
- Very fatigued and/or recently experienced severe sleep disturbances
- Medication known to increase risk of stroke and/or seizure.
- Suffer from severe current substance dependence
- Have a psychosis that is a direct consequence of substance abuse
For control-phase studies:
Subjects. We will recruit 440 participants total in the "Enhancement of Treatment of Delusions in Schizophrenia through Neuromodulation" study H16-01791; The current protocol describes the methods to be used in the Control Phase of our research, during which we will recruit 290 healthy controls between 19 and 60 years in order to establish proof-of-concept for using GTEN tACS in modulating brain oscillations and performance on simple cognitive tasks.
Exclusion criteria for healthy controls:
- history of neurological problems (e.g., stroke, aneurysm, Parkinson's, Multiple Sclerosis, encephalitis, meningitis, etc.)
- History of seizure disorder or family history of seizure disorder. While there is no direct evidence to suggest that tACS increases the risk of seizure in those with a history of seizure disorder in their family, research in this area is still relatively recent (< 15 years). Given the unlikely potential for an unknown elevated risk of seizure, we are including this as a conservative precautionary exclusion factor.
- History of migraines or other types of frequent severe headaches. tACS can induce a headache in those prone to migraines and other forms of severe headaches.
- Presence of metallic implants in head.
- History of severe head injury, frequent loss of consciousness and/or loss of consciousness greater than 30 minutes.
- Recent history of a serious concussion
- Current pregnancy.
- Symptoms of severe fatigued and/or recent experience of severe sleep disturbance.
- Medication known to increase risk of stroke and/or seizure
Sites / Locations
- UBC Hospital - Detwiller Pavilion
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
MCT + Neuromodulation (MCT-N)
Sham/MCT group (MCT- S)
Neuromodulation/Treatment as Usual TAU-N
Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT. Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task. The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects.
Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT. MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects.
Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist. Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task. TAU is a four week waitlist control group.